Celldex Therapeutics, Inc. CLDX R2K

Q: What is the current share price of Celldex Therapeutics, Inc. (CLDX)?

As of 2026-07-14 21:23 PDT, Celldex Therapeutics, Inc. (CLDX) trades at $38.17 on NasdaqCM. Its 52-week range is $20.01 to $39.93.

Q: What is the market capitalisation of CLDX?

Celldex Therapeutics, Inc. (CLDX) has a market capitalisation of $3.00B on NasdaqCM.

Q: What is the P/E ratio of CLDX?

CLDX trades at a trailing price-to-earnings (P/E) ratio of -8.94. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 4.56.

Q: What is the return on equity (ROE) of CLDX?

CLDX has a return on equity (ROE) of -48.94%. Its return on capital employed (ROCE) is -54.02%.

Q: Is CLDX a good stock to buy?

This page provides a data-driven analysis of Celldex Therapeutics, Inc. (CLDX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Biotechnology · United States

https://www.celldex.com

Company Profile ↓

$38.17

+63.40% 1Y

Mkt Cap$3.00B

P/E-8.94

P/B4.56

52W High$39.93

52W Low$20.01

Book Value$6.85

EPS (TTM)$-4.27

Company Overview

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.

Recent Developments

Dec 2025 Revenue of $1.54M (-78.0% YoY); net profit $-258.76M.
Trailing 12 Months Year-on-year growth — revenue -97.8%.
5-Year Trend Long-term compounding — revenue CAGR -13.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	-13.31%
1 Year:	-97.80%

Stock Price Performance

1 Year:	+63.40%
6 Months:	+39.41%
3 Months:	+17.12%
1 Month:	+27.40%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 91% of range

$20.01 $39.93

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)64.08 · Neutral

Price Performance

1M+27.40%

3M+17.12%

6M+39.41%

1Y+63.40%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Revenue declined at -13.3% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-8.94

Industry PE

25.41

Forward P/E

-8.48

PEG Ratio

Book Value

$6.85

Price to Book

4.56

P/S

2,837.51

EV/EBITDA

-6.56

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

-13.31%

Profit 5Y

Revenue (YoY)

-97.80%

Earnings (YoY)

Profitability & Returns

ROCE

-54.02%

ROE

-48.94%

ROA

-30.89%

Profit Margin

0.00%

Op Margin

Gross Margin

0.00%

EPS (Latest Qtr)

$-1.18

EPS (TTM)

$-4.27

Balance Sheet & Liquidity

Debt/Equity

0.42

Quick Ratio

8.78

Current Ratio

8.92

Debt

$1.91M

Total Assets

$511.25M

Current Assets

$534.66M

Working Capital

$483.67M

Ownership

Promoter Holding

0.27%

Chg in Prom Hold

FII / Inst Holding

95.07%

Chg in FII Hold

0.27%

Financial Snapshot

Enterprise Value

$3.00B

Total Revenue (TTM)

$865.00K

EBITDA

$-305.70M

Free Cash Flow

$-126.27M

Operating Cash Flow

$-222.16M

Shares Outstanding

78.49M

Gross Margin

0.00%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	CLDX Celldex Therapeutics, Inc. R2K	38.17	-8.94	$3.00B	0.00%	-54.02%	-48.94%	-13.31%	-
2	LLY Eli Lilly and Company SPX	1,152.54	41.02	$1.03T	0.61%	-	107.46%	7.20%	11.41%
3	JNJ Johnson & Johnson SPX	253.85	29.45	$611.07B	2.23%	14.88%	26.42%	2.43%	4.76%
4	ABBV AbbVie Inc. SPX	244.78	119.40	$432.48B	3.04%	10.47%	-129.24%	1.75%	-29.06%
5	UNH UnitedHealth Group Incorporated SPX	425.19	32.02	$386.13B	2.27%	9.74%	12.18%	10.40%	5.43%
6	MRK Merck & Co., Inc. SPX	120.78	34.02	$298.31B	2.86%	-	18.94%	5.64%	10.01%
7	AZN AstraZeneca PLC NDX	164.50	24.81	$255.12B	1.77%	15.97%	23.48%	9.82%	45.96%
8	TMO Thermo Fisher Scientific Inc. SPX	534.07	29.33	$198.47B	0.40%	8.14%	13.52%	8.81%	12.95%
9	AMGN Amgen Inc. NDXSPX	355.25	24.69	$191.73B	2.84%	18.02%	101.32%	11.77%	5.58%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Mar 2014	Jun 2014	Sep 2014	Mar 2015	Jun 2015	Sep 2015	Mar 2016	Jun 2016	Sep 2016	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	3.83M	3.92M	4.07M	2.76M	941.00K	1.76M	1.43M	715.00K	546.00K	887.00K	2.73M	236.00K	668.00K	3.79M	685.00K	3.48M	153.00K	174.00K	163.00K	407.00K	967.00K	268.00K	1.52M	156.00K	2.50M	3.19M	695.00K	730.00K	-	15.00K
Operating Income	-31.49M	-28.55M	-30.34M	-30.98M	-32.75M	-32.37M	-35.70M	-32.37M	-29.99M	-35.11M	-28.93M	-31.96M	-119.68M	-16.87M	-7.76M	-	-17.94M	-12.26M	-11.84M	-	-12.87M	-11.37M	-14.34M	-	-16.64M	-13.44M	-20.82M	-23.26M	-36.40M	-27.70M	-32.47M	-33.20M	-41.24M	-40.61M	-46.32M	-52.13M	-62.74M	-63.86M	-73.62M	-84.44M
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-32.81M	-35.84M	-42.12M	-53.80M	-56.60M	-67.04M	-78.69M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.42	-0.34	-0.45	-0.49	-0.77	-0.57	-0.62	-0.65	-0.81	-0.56	-0.54	-0.64	-0.81	-0.85	-1.01	-1.18
R&D Expense	27.07M	24.10M	26.18M	25.12M	26.49M	24.66M	27.45M	25.71M	25.01M	25.79M	25.00M	21.91M	21.88M	21.45M	11.92M	-	11.15M	10.08M	11.10M	-	11.70M	9.71M	10.71M	-	12.72M	12.36M	13.56M	17.06M	20.73M	21.57M	26.80M	26.25M	34.53M	31.66M	39.69M	45.26M	52.61M	54.20M	62.93M	73.00M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	15.18M	46.79M	9.27M	11.20M	4.11M	3.59M	5.48M	6.79M	12.74M	9.54M	3.57M	7.42M	4.65M	2.36M	6.88M	7.02M	1.54M
Operating Income	-36.85M	-6.46M	-43.40M	-58.08M	-81.44M	-122.43M	-129.54M	-132.92M	-121.53M	-156.44M	-55.03M	-63.35M	-71.24M	-115.23M	-154.54M	-195.08M	-287.37M
Net Income	-36.52M	-2.53M	-44.80M	-59.12M	-81.55M	-118.08M	-127.20M	-128.53M	-93.03M	-151.18M	-50.88M	-59.78M	-70.51M	-112.33M	-141.43M	-157.86M	-258.76M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-3.51	-2.02	-1.64	-2.40	-2.92	-2.45	-3.90
R&D Expense	26.17M	27.65M	32.44M	47.40M	67.40M	104.38M	100.17M	102.73M	96.17M	66.45M	42.67M	42.53M	53.31M	82.26M	118.01M	163.55M	245.07M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	109.94M	97.99M	125.54M	347.10M	248.01M	337.58M	383.36M	315.62M	155.81M	122.93M	235.84M	-	352.74M	465.63M	792.34M	582.98M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	317.69M	431.69M	747.16M	534.66M
Cash & Equivalents	44.26M	57.00M	21.29M	11.90M	24.90M	169.40M	28.02M	72.11M	42.46M	40.29M	24.31M	11.23M	43.84M	-	29.43M	34.81M	28.36M	28.87M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	347.00K	2.63M	700.00K	2.02M
Total Liabilities	-	-	34.69M	29.27M	29.77M	27.30M	36.35M	47.48M	117.93M	79.25M	31.75M	28.91M	26.48M	-	26.53M	36.46M	45.34M	55.82M
Current Liabilities	-	-	20.21M	14.30M	17.68M	20.35M	24.49M	30.24M	35.22M	27.74M	12.60M	11.64M	14.21M	-	18.61M	31.12M	39.50M	50.99M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.03M	2.54M	3.81M	2.34M
Total Equity	18.13M	73.77M	75.25M	68.72M	95.77M	319.80M	211.66M	290.11M	265.43M	236.37M	124.06M	94.03M	209.36M	-	326.20M	429.17M	747.00M	527.16M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	47.20M	55.88M	66.37M	66.55M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-	-	-	-	-	-98.89M	-113.04M	-99.93M	-75.23M	-46.41M	-40.40M	-	-103.73M	-107.29M	-157.78M	-210.94M
Investing Cash Flow	-	-	-	-	-	-	-50.19M	68.91M	46.47M	29.82M	17.08M	-98.22M	-	89.94M	-105.78M	-290.13M	209.07M
Financing Cash Flow	-	-	-	-	-	-	193.15M	14.48M	51.29M	29.44M	16.26M	171.23M	-	4.08M	218.46M	441.45M	2.39M
Capital Expenditure	-528.00K	-2.10M	-509.00K	-303.00K	-4.22M	-1.93M	-4.88M	-2.75M	-1.79M	-813.00K	-731.00K	-1.55M	-	-1.83M	-1.82M	-1.92M	-2.71M
Free Cash Flow	-	-	-	-	-	-	-103.76M	-115.79M	-101.72M	-76.05M	-47.15M	-41.96M	-	-105.56M	-109.11M	-159.70M	-213.66M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-	-9.71M	5.38M	-6.46M	515.00K

Ratios (Annual)

Figures in %.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-242.8%	-13.8%	-468.4%	-518.5%	-1,981.1%	-3,414.1%	-2,363.9%	-1,958.7%	-953.7%	-1,640.1%	-1,540.2%	-854.1%	-1,531.8%	-4,889.0%	-2,245.3%	-2,778.9%	-18,599.8%
Net Margin %	-240.6%	-5.4%	-483.5%	-527.8%	-1,983.7%	-3,292.8%	-2,321.1%	-1,894.0%	-730.1%	-1,585.1%	-1,424.0%	-805.9%	-1,516.0%	-4,765.6%	-2,054.8%	-2,248.8%	-16,748.0%
ROE %	-49.5%	-3.4%	-65.2%	-61.7%	-25.5%	-55.8%	-43.8%	-48.4%	-39.4%	-121.9%	-54.1%	-28.6%	-	-34.4%	-33.0%	-21.1%	-49.1%
ROCE %	-	-7.2%	-51.9%	-53.8%	-24.9%	-54.8%	-42.1%	-38.2%	-42.2%	-109.2%	-49.4%	-28.6%	-	-34.5%	-35.6%	-25.9%	-54.0%

Shareholding Pattern

Insiders

0.27%

Institutions

95.07%

Public Float

95.32%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Wellington Management Group, LLP	10.91%	8.56M	$324.01M
2	Kynam Capital Management, LP	7.44%	5.84M	$221.07M
3	Blackrock Inc.	6.84%	5.37M	$203.25M
4	FMR, LLC	4.78%	3.75M	$141.90M
5	Point72 Asset Management, L.P.	4.11%	3.23M	$122.25M
6	Vanguard Capital Management LLC	3.77%	2.96M	$112.07M
7	State Street Corporation	3.57%	2.80M	$106.14M
8	Commodore Capital Lp	3.44%	2.70M	$102.07M
9	Price (T.Rowe) Associates Inc	2.66%	2.09M	$78.97M
10	Eversept Partners, LP	2.28%	1.79M	$67.68M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for CLDX

Google News ue, 30 Jun 2026

Is Celldex Therapeutics, Inc. (CLDX) Stock Positioned for Growth Ahead of Potential 2027 Approval? - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxQZDBKempnLWhPRGo3V0RZejhjTktrWXhYMjRSc1psQXh3d3pHM2lwVFZxT0tzSnRvY0d5ZFEtRGpsWHp5X21vcTFpY213LVF6UjRveFdyeHN5SG9BOXMxTEx5VVpYLTI4NVJ5UHdsSF9PbkRVbEd0NHMzaDNjeTlpNWRybzlaLURrZllhNG…

Google News hu, 25 Jun 2026

CLDX Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE5GN1RmSktPSmhDMmdZSk5kQ0I1NXNOTmxrU3ZFcFVjTnluQk9QM0FFYml2TC05S1MtbnZaMU14M1NrMnFlM1J2ejlEb2dsV2V3bGhvMGVCSDZXcW9ndnNkY19jX0RycnZNMzFZRVZTbWFZdzZPSFlhRUN3?oc=5" target="_blank">CLD…

Google News hu, 02 Jul 2026

CLDX Stock Price, Quote & Chart - ChartMill

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9MVFJuQUl6VVdhdWR2UFVpQXpOZWdfVHMwMlJHU3liOXBvZllqSXoxc0lsbTZQVkRsRzBuSHZ6ZzZKN3pvMXFBTUZ4ZUl5MDZSaDE0RC1pLW5vbE5XMENJ?oc=5" target="_blank">CLDX Stock Price, Quote & Chart</a>&nbs…

Google News Mon, 29 Jun 2026

Celldex (CLDX) director receives grant of 26,000 stock options - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxOQVVpbG40SnBYY0l4bTRRN1pkN2t6Sy1rY2Z5cHM4cDk5eTJvTndWZ3lqSWJQbmQwc2EyZHNYbkFxcXRPclM1SUEwVzBEaVFNOU4wUjBRbWo5dEcxd1NJb3FVSTd5dTFwWkxLNHlPcGczWEZmdGVEcVMxMi1NTEZqM3hpNUxfNEV4cFJrcj…

Google News hu, 09 Jul 2026

Celldex Therapeutics (CLDX) Gets Fresh Index Attention As Valuation Debate Heats Up - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxPTzZlbDRuQmxpVUF3Mmh0UjJrdS1iMVdUbzdVYTJaM3pIN1AzanQ1MWJzMjllc3dCdHo1cmx1dHlvZW9XcVJiSU5HUnUzXzBFMTlLc0QwSmhUazNJTnVDRlZ4aDN5bnc0Q0JLemVBVmJ2SlJpaDJZYmcwWW9yZ1hkTDhIM1Bvdk5TX1pkMm…

Google News Sun, 14 Jun 2026

Celldex Therapeutics (CLDX) Stock Valuation Check After Recent Share Price Momentum - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxPX1VNNHg3NFdBQVFVc2IyUThYMGY1X2ZDQlJsWGZKbUpMdWEwc241UWNuVmpwaFp4SDByY2RVTGVHVGNqSEJTaFgxSFphZmsyT1c0NDBWVHhGZlZBWG90SVFKY0tFaUZENlZmTjlFakhGZ3FEbHZkNUlQRUd4VjgyandJdEhKX0pyaHZsTD…

CLDX — Frequently Asked Questions

What is the current share price of Celldex Therapeutics, Inc. (CLDX)?

As of 2026-07-14 21:23 PDT, Celldex Therapeutics, Inc. (CLDX) trades at $38.17 on NasdaqCM. Its 52-week range is $20.01 to $39.93.

What is the market capitalisation of CLDX?

Celldex Therapeutics, Inc. (CLDX) has a market capitalisation of $3.00B on NasdaqCM.

What is the P/E ratio of CLDX?

CLDX trades at a trailing price-to-earnings (P/E) ratio of -8.94. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 4.56.

What is the return on equity (ROE) of CLDX?

CLDX has a return on equity (ROE) of -48.94%. Its return on capital employed (ROCE) is -54.02%.

Is CLDX a good stock to buy?

This page provides a data-driven analysis of Celldex Therapeutics, Inc. (CLDX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Celldex Therapeutics, Inc. CLDX R2K

Company Overview

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Is Celldex Therapeutics, Inc. (CLDX) Stock Positioned for Growth Ahead of Potential 2027 Approval? - Yahoo Finance

CLDX Forecast — Price Target — Prediction for 2027 - TradingView

CLDX Stock Price, Quote & Chart - ChartMill

Celldex (CLDX) director receives grant of 26,000 stock options - Stock Titan

Celldex Therapeutics (CLDX) Gets Fresh Index Attention As Valuation Debate Heats Up - simplywall.st

Celldex Therapeutics (CLDX) Stock Valuation Check After Recent Share Price Momentum - Yahoo Finance

CLDX — Frequently Asked Questions

What is the current share price of Celldex Therapeutics, Inc. (CLDX)?

What is the market capitalisation of CLDX?

What is the P/E ratio of CLDX?

What is the return on equity (ROE) of CLDX?

Is CLDX a good stock to buy?

Explore More